Aims Contemporary 2nd-generation thin-strut drug-eluting stents (DES) are considered
standard of care for revascularization of patients undergoing percutaneous coronary …

Background: Contemporary second-generation drug-eluting stents (DES) have superior
efficacy and safety in comparison with early-generation stents in patients undergoing …

New-generation drug-eluting stents (DESs) represent the standard of care for patients
undergoing percutaneous coronary intervention (PCI). Recent iterations in DES technology …

Importance Stenting small-vessel lesions has an increased adverse cardiovascular event
risk. Very thin-strut or ultrathin-strut drug-eluting stents might reduce this risk, but data are …

The aim of this network meta-analysis is to assess the impact of strut thickness on clinical
outcomes in patients who underwent percutaneous coronary intervention. We searched …

Drug-eluting stents (DESs) are superior to bare metal stents (BMSs) in decreasing
restenosis rates across a wide range of patient and lesion subsets. However, widespread …

Background Treatment of lesions in small vessels was associated with worse clinical
outcome, and various definitions of “small vessels” have been used. Data with novel drug …

Background Drug-eluting stents combining an ultrathin cobalt-chromium stent platform with
a biodegradable polymer eluting sirolimus have been shown to be non-inferior or superior to …

Aims To assess the long-term benefit–risk ratio of drug-eluting (DES) vs. bare-metal stents
(BMS) relative to stent size. Methods and results All 826 consecutive BASKET (BAsel Stent …

Background: Previous meta-analyses have investigated the relative safety and efficacy
profiles of different types of drug-eluting stents (DES) and bare-metal stents (BMS); however …